Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 13, 2005. The report details changes in directors' interests in the company's Ordinary Shares, specifically regarding transactions under employee share plans and dividend reinvestment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions and director shareholdings rather than consolidated financial performance.
Material Changes
The following material changes in director interests were reported:
- GSK Trust Transfer: On January 12, 2005, the GlaxoSmithKline Employee Trust transferred 1,046 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. Directors Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe hold interests in the trust as potential beneficiaries.
- Mr J D Coombe - ShareReward Plan: On January 12, 2005, Mr Coombe acquired 20 Ordinary Shares (10 via personal contribution and 10 via company matching) at a price of £12.18 per share.
- Mr J D Coombe - Annual Investment Plan: On January 13, 2005, Mr Coombe increased his interest by 125 Ordinary Shares at a price of £12.15 per share through the reinvestment of dividends paid on January 6, 2005.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a routine disclosure of director share transactions.
Investor Verification Checklist
- Verify the total number of shares held by Mr J D Coombe following the reported acquisitions.
- Confirm the impact of the 1,046 shares transferred from the GSK Trust on the overall employee share option plan.
- Review the share price fluctuations between the dividend reinvestment price (£12.15) and the ShareReward Plan purchase price (£12.18).